{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:42:43Z","timestamp":1768639363142,"version":"3.49.0"},"reference-count":21,"publisher":"Aging and Disease","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2023]]},"DOI":"10.14336\/ad.2023.0327","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T10:10:35Z","timestamp":1684836635000},"page":"1977","source":"Crossref","is-referenced-by-count":6,"title":["Oligomers and Neurodegeneration: New Evidence"],"prefix":"10.14336","volume":"14","author":[{"given":"Gianluigi","family":"Forloni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2023.0327-1","doi-asserted-by":"crossref","unstructured":"Forloni G, Balducci C (2018). Alzheimer's Disease, Oligomers, and Inflammation. J Alzheimer\u2019s Dis, 62: 1261-1276.","DOI":"10.3233\/JAD-170819"},{"key":"key-10.14336\/AD.2023.0327-2","doi-asserted-by":"crossref","unstructured":"Forloni G, La Vitola P, Balducci C (2022). Oligomeropathies, inflammation and prion protein binding. Front Neurosci, 16: 822420.","DOI":"10.3389\/fnins.2022.822420"},{"key":"key-10.14336\/AD.2023.0327-3","doi-asserted-by":"crossref","unstructured":"Jarrett JT, Lansbury PTJr (1993) Seeding \"one-dimensional crystallization\" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 73: 1055-1058","DOI":"10.1016\/0092-8674(93)90635-4"},{"key":"key-10.14336\/AD.2023.0327-4","doi-asserted-by":"crossref","unstructured":"Ramamoorthy A, Lim MH (2013). Structural characterization and inhibition of toxic amyloid-\u03b2 oligomeric intermediates. Biophys J, 105: 287-288","DOI":"10.1016\/j.bpj.2013.05.004"},{"key":"key-10.14336\/AD.2023.0327-5","doi-asserted-by":"crossref","unstructured":"Cawood EE, Karamanos TK, Wilson AJ, Radford SE (2021). Visualizing and trapping transient oligomers in amyloid assembly pathways. Biophys Chem, 268: 106505.","DOI":"10.1016\/j.bpc.2020.106505"},{"key":"key-10.14336\/AD.2023.0327-6","doi-asserted-by":"crossref","unstructured":"Nguyen PH, Ramamoorthy A, Sahoo BR, Zheng J, Faller P, Straub JE, et al (2021). Amyloid Oligomers: A Joint Experimental\/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chem Rev, 121: 2545-2647","DOI":"10.1021\/acs.chemrev.0c01122"},{"key":"key-10.14336\/AD.2023.0327-7","doi-asserted-by":"crossref","unstructured":"Savelieff MG, Liu Y, Senthamarai RR, Korshavn KJ, Lee HJ, Ramamoorthy A, Lim MHA (2014) small molecule that displays marked reactivity toward copper- versus zinc-amyloid-\u03b2 implicated in Alzheimer's disease. Chem Commun (Camb) 50: 5301-5303.","DOI":"10.1039\/C3CC48473D"},{"key":"key-10.14336\/AD.2023.0327-8","doi-asserted-by":"crossref","unstructured":"Sciacca MF, Kotler SA, Brender JR, Chen J, Lee DK, Ramamoorthy A (2012). Two-step mechanism of membrane disruption by A\u03b2 through membrane fragmentation and pore formation. Biophys J, 103: 702-710.","DOI":"10.1016\/j.bpj.2012.06.045"},{"key":"key-10.14336\/AD.2023.0327-9","doi-asserted-by":"crossref","unstructured":"Pham T, Cheng KH (2020). Exploring the binding kinetics and behaviors of self-aggregated beta-amyloid oligomers to phase-separated lipid rafts with or without ganglioside-clusters. Biophys Chem, 290: 106874","DOI":"10.1016\/j.bpc.2022.106874"},{"key":"key-10.14336\/AD.2023.0327-10","doi-asserted-by":"crossref","unstructured":"Cascella R, Chen SW, Bigi A, Camino JD, Xu CK Dobson CM, et al. (2021). The release of toxic oligomers from alpha-synuclein fibrils induces dysfunction in neuronal cells. Nat Commun, 12: 1814","DOI":"10.1038\/s41467-021-21937-3"},{"key":"key-10.14336\/AD.2023.0327-11","doi-asserted-by":"crossref","unstructured":"Ivanova MI, Lin Y, Lee YH, Zheng J, Ramamoorthy A (2021). Biophysical processes underlying cross-seeding in amyloid aggregation and implications in amyloid pathology. Biophys Chem, 269: 106507","DOI":"10.1016\/j.bpc.2020.106507"},{"key":"key-10.14336\/AD.2023.0327-12","doi-asserted-by":"crossref","unstructured":"Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, et al. (2022). The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci, 23: 53-66","DOI":"10.1038\/s41583-021-00533-w"},{"key":"key-10.14336\/AD.2023.0327-13","doi-asserted-by":"crossref","unstructured":"Imbimbo BP, Ippati S, Imbimbo C, Balducci C (2022). Should we lower or raise levels of amyloid-\u03b2 in the brains of Alzheimer patients? Pharmacol Res, 183: 106390.","DOI":"10.1016\/j.phrs.2022.106390"},{"key":"key-10.14336\/AD.2023.0327-14","doi-asserted-by":"crossref","unstructured":"Sandberg A, Berenjeno-Correa E, Rodriguez RC, Axenhus M, Weiss SS, Batenburg K, et al (2022). A\u03b242 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimers Res Ther, 14: 196.","DOI":"10.1186\/s13195-022-01141-1"},{"key":"key-10.14336\/AD.2023.0327-15","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. (2023). Lecanemab in Early Alzheimer's Disease. N Engl J Med, 388: 9-21","DOI":"10.1056\/NEJMoa2212948"},{"key":"key-10.14336\/AD.2023.0327-16","doi-asserted-by":"crossref","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. (2023). Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. Neurotherapeutics, in press.","DOI":"10.1007\/s13311-022-01308-6"},{"key":"key-10.14336\/AD.2023.0327-17","doi-asserted-by":"crossref","unstructured":"Siemers E, Hitchcock J, Sundell K, Dean R, Jerecic J, Cline E, et al. (2023). ACU193, a Monoclonal Antibody that Selectively Binds Soluble A\u03b2 Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. J Prev Alzheimers Dis, 10: 19-24","DOI":"10.14283\/jpad.2022.93"},{"key":"key-10.14336\/AD.2023.0327-18","doi-asserted-by":"crossref","unstructured":"Shea D, Colasurdo E, Smith A, Paschall C, Jayadev S, Keene CD, et al. (2022). SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. Proc Natl Acad Sci U S A, 119: e221315711","DOI":"10.1073\/pnas.2213157119"},{"key":"key-10.14336\/AD.2023.0327-19","doi-asserted-by":"crossref","unstructured":"Emin D, Zhang YP, Lobanova E, Miller A, Li X, Xia Z, et al. (2022). Small soluble \u03b1-synuclein aggregates are the toxic species in Parkinson's disease. Nat Commun, 13: 5512","DOI":"10.1038\/s41467-022-33252-6"},{"key":"key-10.14336\/AD.2023.0327-20","doi-asserted-by":"crossref","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K, et al. (2022). Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease. Acta Neuropathol Commun, 10: 13","DOI":"10.1186\/s40478-022-01440-6"},{"key":"key-10.14336\/AD.2023.0327-21","doi-asserted-by":"crossref","unstructured":"La Vitola P, Artioli L, Cerovic M, Poletto C, Dacomo L, Leva S, et al. (2023). Repositioning Doxycycline for treating Parkinson\u2019s Disease: evidence from a pre-clinical mouse model. Parkinsonism Relat Dis, 106: 105229","DOI":"10.1016\/j.parkreldis.2022.105229"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:03:31Z","timestamp":1705701811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2023.0327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2023.0327","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}